Therapeutic effect of anti-αv integrin mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease

Hiroki Tomiki, Tomoki Kaneyama, Kunitoshi Kobayashi, Yuji Inaba, Motoki Ichikawa, Hideo Yagita, Byung S. Kim, Chang Sung Koh*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

We examined the regulatory role of αv integrins in the development of Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a model of multiple sclerosis (MS). Blockade of αv integrins by anti-αv integrin monoclonal antibody (mAb) in the effector phase significantly suppressed the development of TMEV-IDD both clinically and histologically. The number of infiltrating mononuclear cells (MNCs) in the CNS was significantly decreased in mice treated with anti-αv integrin mAb. Flow cytometric analysis of cytokine staining revealed that absolute numbers of IFN-γ- and IL-17-producing CD4. + and IFN-γ-producing CD8. + T cells were significantly decreased in the CNS of mice treated with anti-αv integrin mAb. These data suggest that αv integrins may play important roles in the development of TMEV-IDD.

Original languageEnglish (US)
Pages (from-to)25-34
Number of pages10
JournalJournal of Neuroimmunology
Volume268
Issue number1-2
DOIs
StatePublished - 2014

Keywords

  • Demyelinating disease
  • Multiple sclerosis (MS)
  • Theiler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD)
  • αv integrin

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Therapeutic effect of anti-αv integrin mAb on Theiler's murine encephalomyelitis virus-induced demyelinating disease'. Together they form a unique fingerprint.

Cite this